Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

| More on:
Pot stocks are a riskier investment

Image source: Getty Images

North America dominates the marijuana industry with more than 80% market share. Statista.com projects a compound annual growth rate (CAGR) of 14.6% in five years, with a corresponding volume of around US$102.9 billion by 2028.

While the global market size is growing at an accelerating pace, prominent cannabis stocks have nothing to show but losses. Canopy Growth (TSX:WEED), Aurora Cannabis (TSX:ACB), and Tilray Brands (TSX:TLRY) have lost between 85% and 99% in the last three years. As of this writing, all three names are also losing year to date.

Only Curaleaf Holdings (TSX:CURA) stands out and outperforms the TSX thus far in 2023, up 31.22% versus 2.17%, respectively. However, like its industry peers, this cannabis stock has a negative return of 65.6% in three years. The market-beating year-to-date gain is enticing, but staying clear is better unless you’re prepared to lose your investment.

Business performance

Curaleaf is New York-based and not a Canadian firm. The stock debuted on the TSX on December 14, 2023. The $5.3 billion company has 147 local dispensaries, 21 cultivation sites, and is present in 17 states. Based on its investor deck, the cannabis producer and distributor is well-positioned to become a global industry leader because of its footprint in the U.S. and international markets.

Management believes Curaleaf has multiple levers to expand profitability and increase cash generation. In the first three quarters of 2023 (nine months ending September 30, 2023), total revenue increased 7% year over year to a record US$1 billion. In Q3 2023, revenue increased 2% to US$333.2 million versus Q3 2022.

According to its Executive Chairman Boris Jordan, Curaleaf took the final steps in its asset optimization plan during the third quarter. Besides the revenue growth, free cash flow (FCF) from continuing operations reached US$33 million, while cash on the balance sheet was US$118 million.

Growth catalysts

Jordan looks forward to an exciting 2024 following a strong ending in 2023. Moreover, he is upbeat about the coming state and regulatory catalysts and the listing on Canada’s primary stock market. Jordan also notes the early mover advantage in Europe.

Curaleaf’s CEO, Matt Darin, describes the last two quarters as an important evolution for the company. Management reduced the expense structure significantly and scaled back production to accelerate the right-sizing of inventory. He adds that Curaleaf is on the offensive with its innovative new and expanded product offerings.

New York, Ohio, and Germany are growth catalysts, not to mention the market potential in Florida and Pennsylvania. The company opened the newly renovated state-of-the-art Curaleaf Phoenix Airport dispensary in a new location last week.

Curaleaf’s current share price of $7.23 appears to be a good entry point. However, look at the bottom line before investing. After three quarters in 2023, the net loss ballooned 96.8% year over year to US$224.7 million.

Trouble ahead

Curaleaf is one of the leaders in the American cannabis industry, but the headwinds are strong and dangerous. Mounting losses have been the story for most cannabis companies, and Curaleaf is not an exception. The net losses have been consistently growing in the last three years. Profitability remains in doubt despite the grand plans and growth catalysts. Thus, from an investment perspective, Curaleaf spells trouble.   

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »